Advanced search
Publication Cover
Clinical Toxicology Volume 62, 2024 - Issue 2
Submit an article Journal homepage
276
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors

Brian G. Wienera Division of Medical Toxicology, NewYork-Presbyterian Department of Emergency Medicine, Weill Cornell School of Medicine, New York, NY, USACorrespondence[email protected]
View further author information
,
Marlis Gnirkeb Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York, NY, USA;c Department of Health & Mental Hygiene, New York City Poison Control Center, New York, NY, USAView further author information
,
Susi Vassallob Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York, NY, USA;c Department of Health & Mental Hygiene, New York City Poison Control Center, New York, NY, USAView further author information
,
Silas W. Smithb Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York, NY, USA;c Department of Health & Mental Hygiene, New York City Poison Control Center, New York, NY, USA;d Institute for Innovations in Medical Education, New York University Grossman School of Medicine, NYU Langone Health, New York, NY, USAView further author information
&
Mark K. Sub Division of Medical Toxicology, Ronald O. Perelman Department of Emergency Medicine, New York University Grossman School of Medicine, New York, NY, USA;c Department of Health & Mental Hygiene, New York City Poison Control Center, New York, NY, USAView further author information
Pages 131-133 | Received 10 Dec 2023, Accepted 17 Feb 2024, Published online: 12 Mar 2024

References

  • Goldenberg RM, Cheng AYY, Fitzpatrick T, et al. Benefits of GLP-1 (glucagon-like peptide 1) receptor agonists for stroke reduction in type 2 diabetes: a call to action for neurologists. Stroke. 2022;53(5):1813–1822. doi:10.1161/STROKEAHA.121.038151.
  • Marx N, Husain M, Lehrke M, et al. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–1894. doi:10.1161/CIRCULATIONAHA.122.059595.
  • Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomized trials. Lancet Diabetes Endocrinol. 2021;9(10):653–662. doi:10.1016/S2213-8587(21)00203-5.
  • Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center—case series. J Am Pharm Assoc (2003). 2023;63(5):1643–1645. doi:10.1016/j.japh.2023.06.017.
  • Cairns R, Buckley N. Semaglutide exposures reported to the Nsw poisons information Centre: effects of social media marketing and supply chain disruptions. Intern Med J. 2023;53(4):654–655. doi:10.1111/imj.16059.
  • Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12(1):145. doi:10.3390/jcm12010145.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154.
  • Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18(3):203–216. doi:10.1111/dom.12591.
  • Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;2011(10):CD006423. doi:10.1002/14651858.CD006423.pub2.
  • Inc NN, Plainsboro NJ, Ozempic Package Insert. 2023. OZEMPIC (semaglutide) injection, for subcutaneous use. Initial US FDA Approval: 2017.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.